Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : US46116X1019
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 55.93 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.16 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 25.89 | |||||
Beneish M-Score | 99.49 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 147 | |||||
3-Year EBITDA Growth Rate | 20.3 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 26.5 | |||||
3-Year Book Growth Rate | -9.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 42.52 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 28.98 | |||||
9-Day RSI | 38.55 | |||||
14-Day RSI | 42.95 | |||||
6-1 Month Momentum % | 5.97 | |||||
12-1 Month Momentum % | 36.51 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.81 | |||||
Quick Ratio | 7.69 | |||||
Cash Ratio | 6.32 | |||||
Days Inventory | 235.53 | |||||
Days Sales Outstanding | 76.38 | |||||
Days Payable | 104.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.2 | |||||
Shareholder Yield % | 0.04 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 92.71 | |||||
Operating Margin % | -19.96 | |||||
Net Margin % | -14.96 | |||||
FCF Margin % | -10.81 | |||||
ROE % | -11.9 | |||||
ROA % | -9.97 | |||||
ROIC % | -76.7 | |||||
3-Year ROIIC % | 78.24 | |||||
ROC (Joel Greenblatt) % | -112.68 | |||||
ROCE % | -15.57 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 100 | |||||
PS Ratio | 12.8 | |||||
PB Ratio | 6.76 | |||||
Price-to-Tangible-Book | 6.76 | |||||
EV-to-EBIT | -59.93 | |||||
EV-to-Forward-EBIT | 89.46 | |||||
EV-to-EBITDA | -60.21 | |||||
EV-to-Forward-EBITDA | 271.59 | |||||
EV-to-Revenue | 11.96 | |||||
EV-to-Forward-Revenue | 7.07 | |||||
EV-to-FCF | -110.68 | |||||
Price-to-Net-Current-Asset-Value | 7.12 | |||||
Price-to-Net-Cash | 9.14 | |||||
Earnings Yield (Greenblatt) % | -1.67 | |||||
FCF Yield % | -0.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITCI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 563.435 | ||
EPS (TTM) ($) | -0.87 | ||
Beta | 0.86 | ||
Volatility % | 35.63 | ||
14-Day RSI | 42.95 | ||
14-Day ATR ($) | 2.018692 | ||
20-Day SMA ($) | 74.5025 | ||
12-1 Month Momentum % | 36.51 | ||
52-Week Range ($) | 45.5 - 84.89 | ||
Shares Outstanding (Mil) | 105.67 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Intra-Cellular Therapies Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(ITCI)'s stock price today?
When is next earnings date of Intra-Cellular Therapies Inc(ITCI)?
Does Intra-Cellular Therapies Inc(ITCI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |